State Street’s Osiris Therapeutics, Inc. Common Stock OSIR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q2 | – | Sell |
-11,600
| Closed | -$220K | – | 3917 |
|
|
2019
Q1 | $220K | Hold |
11,600
| – | – | ﹤0.01% | 3561 |
|
|
2018
Q4 | $157K | Buy |
+11,600
| New | +$130K | ﹤0.01% | 3599 |
|
|
2017
Q1 | – | Sell |
-288,550
| Closed | -$1.41M | – | 3729 |
|
|
2016
Q4 | $1.41M | Buy |
288,550
+1,375
| +0.5% | +$7.04K | ﹤0.01% | 3208 |
|
|
2016
Q3 | $1.42M | Buy |
287,175
+2,863
| +1% | +$14.7K | ﹤0.01% | 3092 |
|
|
2016
Q2 | $1.45M | Sell |
284,312
-9,734
| -3% | -$52.4K | ﹤0.01% | 3159 |
|
|
2016
Q1 | $1.68M | Buy |
294,046
+11,117
| +4% | +$77.6K | ﹤0.01% | 3064 |
|
|
2015
Q4 | $2.94M | Buy |
282,929
+396
| +0.1% | +$5.38K | ﹤0.01% | 2827 |
|
|
2015
Q3 | $5.22M | Sell |
282,533
-6,975
| -2% | -$135K | ﹤0.01% | 2513 |
|
|
2015
Q2 | $5.63M | Buy |
289,508
+6,049
| +2% | +$107K | ﹤0.01% | 2572 |
|
|
2015
Q1 | $4.99M | Buy |
283,459
+6,706
| +2% | +$113K | ﹤0.01% | 2565 |
|
|
2014
Q4 | $4.42M | Buy |
276,753
+1,814
| +0.7% | +$24.3K | ﹤0.01% | 2627 |
|
|
2014
Q3 | $3.47M | Sell |
274,939
-2,584
| -0.9% | -$36.9K | ﹤0.01% | 2739 |
|
|
2014
Q2 | $4.33M | Sell |
277,523
-4,272
| -2% | -$62.8K | ﹤0.01% | 2668 |
|
|
2014
Q1 | $3.7M | Buy |
281,795
+19,304
| +7% | +$302K | ﹤0.01% | 2750 |
|
|
2013
Q4 | $4.22M | Sell |
262,491
-5,033
| -2% | -$80.2K | ﹤0.01% | 2671 |
|
|
2013
Q3 | $4.45M | Buy |
267,524
+12,756
| +5% | +$189K | ﹤0.01% | 2598 |
|
|
2013
Q2 | $2.57M | Buy |
+254,768
| New | +$2.68M | ﹤0.01% | 2842 |
|
Other funds holding OSIR
State Street's OSIR Position: Q2 2019 in Review
State Street sold out of Osiris Therapeutics, Inc. Common Stock (OSIR) in Q2 2019, closing a stake of 11,600 shares — an estimated $220K sold.
State Street first reported a position in OSIR in Q2 2013 and held it in 17 quarters. The position peaked at $5.63M in Q2 2015. 1 fund tracked by Wall St. Rank holds OSIR as of Q2 2019.
- State Street reported no remaining Osiris Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
- State Street sold 11,600 Osiris Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $220K.
- State Street first reported a position in Osiris Therapeutics, Inc. Common Stock in Q2 2013 and held it in 17 quarters.
- State Street's Osiris Therapeutics, Inc. Common Stock position peaked at $5.63M in Q2 2015.
- 1 fund tracked by Wall St. Rank held Osiris Therapeutics, Inc. Common Stock as of Q2 2019.
Based on State Street's 13F filing for Q2 2019, filed 14 Aug 2019.